E STROGENS ARE A class of steroid hormones that play a critical role in the development of the normal breast and in the genesis of breast cancer (1, 2) . Estrogens mediate their cellular responses through two distinct intracellular receptors, estrogen receptor (ER)-␣ (ER␣) and ER␤, which are encoded by separate genes (3) . In the cell systems tested to date, after activation by ligand binding, each ER regulates the transcription of unique but overlapping sets of target genes (4), although both receptors are capable of activating synthetic reporter plasmids driven by estrogen response elements (EREs) or activator protein 1 (AP-1) sites. The two ERs have been shown to play different roles in the reproductive physiology of mammals (5, 6) . For example, a high ER␣:ER␤ ratio correlates well with high levels of cellular proliferation, whereas predominance of functional ER␤ over ER␣ correlates with lower levels of proliferation (7) (8) (9) . Ectopic expression of ER␣ in estrogen-sensitive breast cancer cell lines, such as MCF7 and T47D, leads to no major changes in proliferation rate, whereas expression of exogenous ER␤ in these cells leads to a drastic reduction in cell growth rates in culture as well as in nude mouse xenografts (10, 11) . This correlation with the proliferative state also holds in a physiological setting in that during the pre and peripubertal phases of rodents, which are periods of high proliferation, ER␣ expression predominates in the mammary epithelium, whereas, during lactation, in which there is minimal mammary epithelial mitogenesis, the amount of ER␤ protein is 5 times that of ER␣ in the mammary epithelium (12, 13) . Additionally, in the ER␣ null mouse mammary gland, even pharmacological doses of estrogen are ineffective in inducing robust growth of mammary epithelium, indicating that ER␤ does not mediate proliferative effects of estrogens in the mammary epithelium (2) .
Although the role of ER␤ in the etiology of human breast cancer has not been well characterized, ER␣ expression and function appears to be an important factor for prognosis of human breast cancer. ER␣-positive breast cancers correlate well with the proliferation of differentiated tumor phenotypes, and the majority of these tumors respond well to antihormonal therapy (14) . Tamoxifen, a mixed antiestrogen, is clinically useful in the management of ER␣-positive met-astatic breast cancer and in the prevention of breast cancer, and has improved the survival of women with ER␣-positive breast cancer (15, 16) . However, longterm management of breast cancer with tamoxifen is associated with tamoxifen resistance, increased endometrial cancer risk, and other undesirable side effects (15) (16) (17) . Tamoxifen-resistant breast cancers respond well to the pure steroidal antiestrogen ICI 182,780 (Faslodex), which has been shown to downregulate the levels of ER␣ by causing proteasomedependent degradation (18) (19) (20) (21) . Thus, a key issue in the characterization of promising therapeutic molecules to treat breast cancers is to determine their specific effects on ER␣and ER␤ responsiveness.
Both epidemiological and physiological studies suggest that phytochemicals from vegetables and fruits represent a largely untapped source of potential anticancer molecules (22) (23) (24) (25) (26) (27) . One such phytochemical is indole-3-carbinol (I3C), an autolysis product of glucosinolates present in Brassica vegetables such as broccoli, cabbage, and cauliflower. Dietary exposure to I3C reduced tumor occurrence and decreased the multiplicity of spontaneous as well as carcinogen-induced mammary tumor formation in rodent model systems (28, 29) . I3C also tested positive as a chemopreventative agent in several short-term bioassays relevant to carcinogen-induced DNA damage, tumor initiation and promotion, and oxidative stress (30) . We and others have demonstrated that I3C and its natural dimer, 3Ј-3Ј-dindolylmethane (DIM) have direct antiproliferative effects on human reproductive cancer cells (31) (32) (33) (34) (35) . For example, I3C induces a G1 cell cycle arrest of both estrogen-sensitive MCF7 and estrogeninsensitive MDA-MB-231 breast cancer cells (36) that is accompanied by a transcriptional down-regulation of cyclin-dependent kinase (CDK) 6 (39) , and an inhibition of CDK2 activity in which the size distribution of associated cyclin E forms and subcellular localization of the CDK2 protein complex is altered (37) . I3C also cooperates with tamoxifen to more effectively induce a G1 cell cycle arrest and ablated phosphorylation of the retinoblastoma protein (Rb) in MCF7 breast cancer cells (32) . This indole has also been shown to elicit antiestrogenic effects and decrease the level of phosphorylated ER␣ protein (38) , although the underlying mechanism was not examined.
In this study, we report that at concentrations of I3C effective in causing a G1 cell cycle arrest, I3C differentially regulates the expression and function of ER␣ and ER␤. This indole strongly down-regulated ER␣ expression due to a loss of promoter activity, which disrupts the regulated expression of exogenous and endogenous genes by 17␤-estradiol (E) and by propyl pyrazole triol (PPT), a highly selective agonist for ER␣, without altering ER␤ expression. Furthermore, we report that the loss of ER␣ expression is accompanied by an increase in functional ER␤ that can bind to an ERE and increase ER␤-associated ERE and AP-1-driven transcriptional activity. Thus, our study demonstrates that treatment with I3C results in a significantly higher ER␤:ER␣ ratio of functional ER subtypes that is highly associated with antiproliferative status of human breast cancer cells.
RESULTS

I3C Down-Regulates ER␣ Protein Levels without Altering ER␤ Protein Levels in MCF7 and T47D Human Breast Cancer Cells
Estrogen-responsive breast cancer cells express two ER subtypes (ER␣ and ER␤) that are encoded by distinct genes (3). ER␣ responsiveness is generally associated with proliferative mechanisms, whereas dominance of ER␤ responsiveness has been linked to antiproliferative processes (2, 3, 11, 12) . To examine the relative expression levels of ER␣ and ER␤ under I3C-mediated growth-arrested conditions (36) , estrogen-responsive MCF7 and T47D human breast cancer cells were treated with various doses of I3C for 48 h, and Western blots of total cell extracts were probed for either ER␣ or ER␤ protein. The levels of ␤-actin were used as a gel loading control. As shown in Fig.  1A , I3C strongly down-regulated the level of ER␣ protein in both cell lines in a dose-responsive manner, without causing any effect on the level of ER␤ protein.
Western blots showed that 1 M E was unable to reverse the I3C-mediated down-regulation of ER␣ protein (data not shown), suggesting that I3C does not act as an ER antagonist in agreement with our previous report demonstrating that I3C does not bind ERs (32) . Figure 1B (top panel) shows the quantification by densitometric measurement of ER␣ and ER␤ protein levels in cells treated at various I3C concentrations in comparison to the G1 cell cycle arrest induced by I3C in MCF7 cells as determined by flow cytometry. The overall dose-dependent profile of down-regulation of ER␣ protein levels strongly correlated with that of the increase in G1 phase arrested cells and down-regulation of S phase cells. The half-maximal indole responses were approximately 100 M I3C, and the maximal responses without any apoptotic effects were observed at 200 M I3C. The data shown in Fig. 1B are for MCF-7 cells, although the same effects were observed with T47D human breast cancer cells (data not shown). Taken together, these data show that the maximal indole concentrations, which induce a G1 cell cycle arrest, result in a predominantly ER␤-responsive cellular background, and therefore 200 M I3C was the dose used throughout the remainder of this study.
To determine the kinetics of I3C induced downregulation of ER␣ protein, MCF7 and T47D cells were treated with or without 200 M I3C for different durations, and total cell extracts were examined for the levels of ER␣ and ER␤ protein, as well as that of CDK2 protein as a loading control (36) , by Western blot analysis. As shown in Fig. 2 , the I3C-mediated downregulation of ER␣ protein is a rapid response that occurs within the first 24 h of indole treatment in both A, MCF7 and T47D cells were treated with the indicated concentrations of I3C for 48 h. Isolated protein extracts were fractionated using SDS-PAGE and electrophoretically transferred to nitrocellulose membranes, and immunoblots were probed with antibodies specific for ER␣ and ER␤. ␤-Actin protein was used as a gel loading control. The band intensities were quantified using densitometry, and the bar graph represents relative values for ER␣ and ER␤ normalized to actin values. B, MCF7 cells were exposed to DMSO or indicated doses of I3C for 48 h, hypotonically lysed in a solution containing propidium iodide, and subjected to flow cytometric analysis based on DNA content. This analysis is depicted as a bar graph with SE bars. cell lines and is maintained throughout the time course. The results with T47D cells show that I3C down-regulated ER␣ protein levels without altering ER␤ levels within 6 h of I3C treatment. Although the earliest time point shown for MCF7 cells is 24 h, I3C down-regulated ER␣ protein production with a similar overall kinetic profile as observed in T47D cells. The levels of CDK2 remained unaltered throughout each time course as expected. Thus, our results show for the first time that an antiproliferative phytochemical can selectively down-regulate the production of the ER␣ without altering the level of ER␤ in human breast cancer cells. In all of the following experiments, similar results were obtained for MCF7 and T47D cells, although only the data using MCF7 cells are shown.
I3C Selectively Down-Regulates ER␣ Transcript Levels and Promoter Activity
The relatively rapid down-regulation of ER␣ protein by I3C suggested that this indole might be selectively regulating the transcription of this ER subtype. To test whether I3C down-regulated ER␣ mRNA levels, MCF7 cells were treated with dimethylsulfoxide (DMSO) as the vehicle control, 200 M I3C, 1 M tamoxifen, an antiestrogen known to cause G1 cell cycle arrest in MCF7 cells (17, 32) , or 200 M tryptophol for 48 h. Tryptophol is structurally similar to I3C, differing by one carbon, but fails to induce a growth arrest (39) and therefore can be used as an indole structural control. Total RNA was isolated and the levels of ER␣ and ER␤ transcripts were examined by RT-PCR analysis using gene-specific oligonucleotide primers. Expression of ER␣ and ER␤ transcripts were compared with glyceraldehyde phosphate dehydrogenase (GAPDH), which is constitutively expressed. As shown in Fig. 3 , I3C treatment abrogated the expression of ER␣ mRNA without any effect on ER␤ mRNA levels. Exposure to either tamoxifen or tryptophol had no effect on ER␣ or ER␤ transcript levels, demonstrating that the I3C down-regulation of ER␣ transcripts is not a fortuitous consequence of the growth arrest or a nonspecific indole effect.
The ER␣ gene promoter has been shown to have two transcriptional start sites (denoted A and B), although precise function and regulation of each site have not been completely characterized. Sp1 transcription factor binding sites have been shown to be critical for expression of ER␣ (40) . I3C has been shown to transcriptionally down-regulate CDK6 by disrupting Sp1 binding to consensus binding sites (39) . To test whether I3C regulates ER␣ promoter activity, MCF7 cells were transfected with two different ER␣ promoter luciferase reporter plasmids. One reporter plasmid contains 3.2 kb of the ER␣ promoter (Ϫ3200-luc) with both transcriptional start sites, and the other construct contains a 0.7-kb fragment of the ER␣ promoter (Ϫ700-luc) with only transcriptional start site A (see diagram in Fig. 4A , bottom panel). Transfected cells were treated with or without I3C for 24 h, and the luciferase-specific activity was monitored in both sets of transfected cells. Two controls routinely used in these experiments are transfection of the empty pGL2 vector as well as transfection of a construct expressing the luciferase reporter under the constitutive cytomegalovirus (CMV) promoter. I3C did not affect the production of luciferase in either control (data not shown). As shown in Fig. 4A , I3C treatment strongly down-regulated the promoter activity [measured in relative light units (RLU)] of the Ϫ3200-luc reporter gene, which contains both ER␣ transcriptional start sites. In contrast, I3C had no effect on activity of the Ϫ700 ER␣ promoter fragment, which has been observed to have significant activity when transfected in MCF7 cells. Both plasmids show considerable luciferase activity in untreated MCF7 cells upon transfection in that in the absence of I3C the Ϫ3200-Luc reporter plasmid displayed approximately 1020 RLU per g protein, and the Ϫ700-Luc reporter plasmid displayed approximately 800 RLU per g protein. Thus, the loss of I3C down-regulation of promoter activity from the Ϫ700-Luc reporter plasmid reflects the loss of a putative g of isolated total RNA was reverse transcribed using random primers and Mu-MLV. cDNA (400 ng) was in the PCR using specific primers for ER␣ and ER␤. The PCR products were electrophoretically fractionated in 1% agarose gels, and GAPDH levels were used as a loading control.
I3C-regulated element rather than simply an inactive promoter fragment. These results demonstrate that the I3C down-regulation of ER␣ gene products can be accounted for by a concomitant down-regulation of ER␣ promoter activity. Consistent with this promoter effect, I3C failed to strongly ablate mRNA levels of ER␣ in MCF7 cells transfected with a plasmid containing the ER␣ gene constitutively expressed from a CMV promoter as shown in Fig. 4B .
I3C Disrupts ER␣-Responsive ERE Activity and Estrogen-Induced Expression of Endogenous Progesterone Receptor
To examine the functional consequences of I3C treatment on ER responsiveness, MCF7 cells were grown in steroid-deficient media supplemented with 10% charcoal dextran-stripped fetal bovine serum, transfected with a pGL2 luciferase reporter plasmid containing the consensus vitellogenin ERE (Vit-3-EREluc). In this assay, I3C was tested for its effectiveness in disrupting ERE-driven luciferase expression induced by E, or by the ER␣-specific agonist PPT. PPT has been shown in several systems to be highly ER␣ specific, possessing 410-fold higher affinity for ER␣ than for ER␤ (4) . Transfection of the empty pGL2 luciferase vector provided a negative control for background luciferase activity. The cells were pretreated with DMSO or 200 M I3C for 24 h, and then incubated with the indicated combinations of DMSO, 200 M I3C, 10 nM E, and 100 nM PPT for an additional 24 h. ERE
Fig. 4. I3C Decreases ER␣ Promoter Activity
A, MCF7 cells were transfected with luciferase reporter plasmids constructs containing either the Ϫ3.2 kb upstream region of the ER␣ gene promoter (Ϫ3200-luc) or the Ϫ700 bp upstream region of the ER␣ gene promoter (Ϫ700-luc). The two ER␣ transcription start sites are denoted as B and A; the B site is 1994 bp upstream of the A site. Cells were treated 24 h post transfection with DMSO or 200 M I3C for 24 h, and the relative luciferase activity was evaluated in lysed cells using the Promega luciferase assay kit. Two controls (data not shown) employed were the empty control pGL2 (RLU ϭ 0.1-0.5) and constitutive CMV promoter (RLU in millions). Bar graphs indicate relative luciferase activity normalized to the protein input with SE. The level of observed promoter activity in the absence of I3C was approximately 1020 RLU per g protein for the Ϫ3200-Luc reporter plasmid and approximately 800 RLU per g protein for the Ϫ700-Luc reporter plasmid. B, MCF7 cells were transfected with plasmids containing ER␣ cDNA for ectopic overexpression. Control and ER␣ overexpressing MCF7 cells were treated with DMSO or 200 M I3C for 48 h. Total RNA isolated from these cells was subjected to reverse transcription followed by PCR with primers specific for ER␣ or GAPDH. PCR products were electrophoresed and visualized using a UV transilluminator. activity was measured in cell extracts as RLUs and normalized to total protein. As shown in Fig. 5 , treatment with either E or PPT stimulated a robust increase in ERE activity. Incubation with I3C ablated the stimulated ERE activity by both ER agonists (I ϩ E; I ϩ PPT). Treatment with I3C alone induced a small but reproducible increase in ERE and AP-1 reporter plasmid activities, which as described later is likely due to activation of ER␤.
To assess whether I3C can disrupt the regulated expression of an endogenous estrogen-responsive gene, MCF7 cells were treated with combinations of 200 M I3C and either 10 nM E or 100 nM PPT. Cells were cultured in steroid-deficient media supplemented with 10% charcoal dextran-stripped fetal bovine serum. Using specific oligonucleotide primers, the expression of progesterone receptor transcripts, an estrogen target gene, was examined in comparison to GAPDH, which is constitutively expressed. As shown in Fig. 6 , the robust E and PPT stimulation of PR transcripts is strikingly ablated in the presence of I3C. This result demonstrates that I3C down-regulation of ER␣ has functional consequences in that it results in disruption of total activity at a given ERE, as well as in ablation of E or PPT to stimulate expression of ER␣-dependent genes such as progesterone receptor.
Differential Effects of I3C on the Binding of ER␣ and ER␤ to the ERE
Given that I3C can disrupt ERE-driven transcriptional activity as well as induction of estrogen responsive genes in MCF7 cells, an in vitro binding assay was employed to evaluate effects of I3C treatment on the ability of ER␣ or ER␤ to bind to an ERE. Streptavidinagarose beads were conjugated with biotinylated oligonucleotides encoding the ERE from the vitellogenin promoter, and then incubated with cell lysates isolated from I3C-treated and untreated MCF7 or MDA-MB-231 breast cancer cells which are ER␣Ϫ/ER␤ϩ. ERE bound proteins were eluted in a high-salt buffer, electrophoretically fractionated in sodium dodecyl sulfate (SDS) polyacrylamide gels, and immunoblotted for ER␣ or ER␤ using subtype-specific antibodies. As shown in Fig. 7A (left panel) , I3C down-regulated the level of ERE-bound ER␣ protein in MCF7 cells, which is accounted for by the I3C down-regulation of total ER␣ protein levels (Fig. 7B, left panel) . Strikingly, even though the total level of ER␤ protein did not change (Fig. 7B, right panel) after indole treatment, I3C significantly increased the level of ER␤ that can bind to the ERE (Fig. 7A, right panel) . Quantification of these results demonstrated that I3C reverses the ratio of functional ER␤ to ER␣ in MCF7 cells, effectively leading to a primarily ER␤-responsive cellular background. Cells were harvested in trizol, and 2 g of total RNA was subjected to reverse transcription using random primers and Mu-MLV. This cDNA (400 ng) was subjected to PCR with primers specific for progesterone receptor. GAPDH transcript levels served as loading control.
Highly selective ER␤ agonists are not currently available. Therefore, to test whether I3C alters ER␤ activity, MDA-MB-231 cells were used because this human breast cancer cell line expresses ER␤ but is deficient in ER␣ production due to gene silencing by promoter methylation (40) . We have previously demonstrated that I3C is effective in causing cell cycle arrest in MDA-MB-231 breast cancer cells (36) . As shown in Fig. 7A (right panel) , I3C treatment caused a 6-fold increase in ER␤ binding to the ERE without altering total cellular levels of ER␤ (Fig. 7B right panel) . The MDA-MB-231 cells do not express ER␣ in the presence or absence of I3C (Fig. 7B, right panel) , and therefore DNA binding was not assessed for this ER subtype.
I3C Treatment Increases ER␤-Mediated ERE and AP-1 Activity in MDA-MB-231 Breast Cancer Cells
To assess I3C regulation of ER␤ activity in cells expressing ER␤ in the absence of ER␣, MDA-MB-231 cells were transfected with luciferase reporter plasmids containing highly estrogen-responsive DNA elements, Vit-3ϫERE or AP-1. Cells were then cultured in media supplemented with steroid-deficient fetal bovine serum in the presence of the indicated combinations of 10 nM E and 200 M I3C for 24 h, and relative luciferase-specific activity was measured as described in Materials and Methods. A parallel experiment was performed with 1 M tamoxifen instead of E. As shown in Fig. 8A , I3C treatment caused a reproducible activation of the ERE-containing reporter plasmid activity (DMSO vs. I3C) in the absence or presence of 17␤-estradiol. As expected, E had no effect on ERE activity in this ER␣-deficient cell line. As shown in Fig.  8B , I3C treatment also increased AP-1-driven luciferase activity independent of E treatment. As shown in Fig. 8C , the robust I3C-mediated increase in AP-1 activity was partially reversed by tamoxifen, in accordance with previous reports that suggest that in breast cancer cells, tamoxifen can act as a pure ER␤ antagonist (47) . These results, together with the increased binding of ER␤ to the ERE, suggest that I3C enhances ER␤ responsiveness even in the absence of an ER agonist.
I3C Treatment Disrupts Estrogen-Induced Proliferation of MCF7 Breast Cancer Cells
The growth of estrogen-responsive human breast cancer cell lines, such as MCF7 and T47D cells, is strongly stimulated by estrogens when cultured in steroid-deficient conditions (17) . Therefore, MCF7 cells grown in steroid-deficient media containing 10% charcoal dextran-stripped fetal bovine serum were employed to test whether I3C can block cell proliferation induced by either E or PPT. Cell cycle effects were examined by flow cytometry of propidium iodide-stained nuclei after 48 h in culture in the indicated conditions. As shown in Fig. 9A (left panels), treatment with either 10 nM E or 100 nM PPT induces cell-cycle progression in that both agonists strongly reduced the number of cells in the G1 phase of the cell cycle (ϳ66% to ϳ46%) and stimulated a significant increase in S phase cells (ϳ29% to ϳ50%). Exposure to 100 M I3C for 24 h blocked the stimulation in S phase cells and decrease in G1 phase cells by either E or by the ER␣-specific agonist PPT (Fig. 9A, right panels) . In the steroid-free conditions of this experiment, the cells remained relatively growth arrested in the presence or absence of I3C, and the overall DNA content was not altered (Fig.  9A, top panels) . The cell cycle effects observed in three independent experiments were quantified, and as shown in Fig. 9B , the overall distribution of DNA content of cells treated with a combination of I3C and either E or PPT was nearly identical to that of cells not exposed to any estrogens. Similar results were also observed using human T47D breast cancer cells (data not shown). Thus, key cellular consequences of the selective I3C disruption of ER␣ expression are loss of total cellular ER␣ activity and estrogen-dependent proliferation. 
DISCUSSION
Human estrogen-responsive breast cancer cell lines that are highly proliferative, such as MCF7 and T47D, express high levels of ER␣ compared with normal mammary epithelial cells and other breast cancer cells. Overexpression of exogenous ER␤ in these cell lines has been shown to lead to a marked arrest in growth and disruption of 17␤-estradiol-induced proliferation (10, 11). An emerging concept that developed from these and other studies is that an increased ER␣:ER␤ ratio in estrogen-responsive mammary cancer cells is conducive to cell growth whereas an increased ER␤:ER␣ ratio is generally linked to antiproliferative contexts (7) (8) (9) 41) . In the present study using both MCF7 and T47D breast cancer cell lines, we demonstrate that the I3C growth arrest is accompanied by a selective down-regulation of ER␣ expression and responsiveness, while ER␤ levels remain unaltered. I3C treatment also caused a reproducible enhancement of functional ER␤ as monitored by its binding to the vitellogenin ERE. Thus, I3C reversed the functional ER ratio to primarily an ER␤-responsive background, which correlated well with the potent antiproliferative effects of this indole. Thus, a novel response of I3C is the selective transcriptional downregulation of ER␣ expression without altering protein or transcript levels of ER␤.
Strong correlation has been found between cellular proliferation in normal mammary glands and mammary cancers to the relative levels of ER␣ and ER␤. ER␤ expression levels were higher in normal human mammary epithelial cells in vivo, and in nonproliferative benign breast disease compared with its levels in more malignant preinvasive lesions, such as ductal carcinoma in situ, which usually overexpress ER␣ (7, 8, 14) . The roles of ER␣ and ER␤ in mammary epithelial cell proliferation have been evaluated in knock out mouse models (2, 3), as well as in human breast cancer cell lines in culture (10, 11) . The proliferative effects of estrogens are thought to be mediated primarily by ER␣, because ablation of ER␣ in mouse mammary glands leads to a severely underdeveloped mammary epithelium. The ER␣ null epithelium still expresses ER␤, and the mammary epithelial growth impairment cannot be rescued by administration of pharmacological levels of estrogens (2) . This genotype is also associated with a major decrease in the development of estrogen-unresponsive mammary cancers indicating that estrogen signaling through ER␣ plays a major role in proliferation of normal mammary epithelial cells in vivo as well as in hormone-responsive and hormoneunresponsive mammary carcinogenesis (1, 2). Current breast cancer therapeutic drugs that inactivate ER␣, such as tamoxifen, have been shown to prevent development of carcinogen-induced rat mammary tumors (16) and prevent breast cancer in humans (42) , which further establishes a positive correlation between ER␣ and cellular proliferation as well as mammary carcinogenesis. In contrast to the information currently available on ER␣, the precise significance of ER␤ in human breast cancers remains unclear, although ER␤ is thought to play a role in inhibiting mammary epithelial cell proliferation during lactation and involution in the normal mammary gland. ER␤ null mice show normal development of the mammary gland until lactation. Lactating wild-type mice show a marked cessation of mammary epithelial cell proliferation, whereas ER␤ null mice show significant levels of mammary epithelial cell proliferation during lactation (43) .
Our observation that I3C down-regulates ER␣ gene expression by an inhibition of promoter activity is consistent with the results of our previous studies demonstrating that I3C strongly down-regulates CDK6 promoter activity in human breast cancer cells that undergo a G1 cell cycle arrest (36, 39) . I3C disrupts the function of the Sp1 and ETS transcription factors at a composite element in the CDK6 promoter (31, 39) . Interestingly, the kinetics of ER␣ down-regulation by I3C is strikingly similar to that of CDK6 (39), suggesting A, MCF7 cells were grown in steroid-deficient media supplemented with 10% dextran charcoal-stripped fetal bovine serum. Cells were pretreated with DMSO or 100 M I3C for 24 h, and then treated with DMSO or 100 M I3C (I) in the presence or absence of 10 nM E or 100 nM PPT for 24 h. Cells were harvested in PBS and stained with a hypotonic solution containing propidium iodide. Stained nuclei were subjected to flow cytometry analysis as described in Materials and Methods. B, The flow cytometry results from three independent experiments were quantified. Bar graph indicates percent cells in G1, S, and G2 phases with SE bars.
that an analogous regulatory mechanism may be operating on ER␣. Consistent with this concept, I3C inhibited a luciferase reporter plasmid containing a 3200-bp ER␣ promoter fragment, but had no effect when the reporter plasmid was linked to a 700-bp 5Ј-deleted promoter fragment. The larger ER␣ promoter fragment contained both the transcription start sites (B at Ϫ1994 bp and A), suggesting the existence of an I3C-regulated transcriptional element in the ER␣ promoter between Ϫ3200 and Ϫ700. This region contains binding sites for Sp1, the binding of which is disrupted by I3C leading to transcriptional down-regulation of CDK6 (39) . We are currently in the process of determining the precise location of the I3C-regulated element and of identifying which transcription factor(s) binding is/are targeted by I3C.
Several lines of evidence show that a key consequence of the I3C down-regulation of ER␣ transcription is the loss of ER␣ responsiveness. I3C ablates the stimulation of growth and activation of an ERE reporter plasmid by PPT, a highly selective ER␣ agonist that possesses a 400-fold higher affinity for ER␣ than ER␤ (4). Furthermore, I3C treatment blocks the E and PPTstimulated expression of progesterone receptor, a known ER␣-responsive gene. Interestingly, PPT stimulates growth of MCF7 and T47D cells to the same extent as 17␤-estradiol. I3C also appears to activate ER␤ by inducing a significant increase in the DNA binding form of ER␤, and by stimulating vitellogenin ERE reporter plasmids in MDA-MB-231 breast cancer cells that express ER␤, but not ER␣. It is interesting to note that I3C is effective in causing a cell cycle arrest in MDA-MB-231 breast cancer cells (36) , and this correlates well with activation of ER␤. These breast cancer cells are unlikely to express any unusual ER␣ isoforms because this gene is heavily silenced by methylation (40) . We are currently attempting to elucidate the mechanism by which I3C activates ER␤ function in human breast cancer cells.
Estrogen signaling has been shown to be essential for the proliferation of normal mammary epithelial cells and is a key risk factor in the development of estrogenresponsive as well as estrogen-unresponsive breast cancer (1, 3, 14, 17, 42) . It has been established that benign lesions showing elevated levels of ER␣ pose a higher risk for development of malignant breast cancer linking ER␣ to estrogen-mediated increase in tumorigenicity in rodents and humans (44, 45) . Conceivably, a potential prophylactic use of I3C is to down-regulate ER␣ in high-risk but benign ER␣ overexpressing premalignant cell populations, thus effectively dampening the promotion of premalignant lesions to malignancy by estrogens. Furthermore, I3C has been shown to cooperate with the antiestrogen tamoxifen in that a combination of tamoxifen and I3C caused a more potent growth arrest than either compound alone (32) . These findings suggest that this indole could be used as a potential adjuvant therapeutic for estrogenresponsive breast cancer. Taken together, our results implicate I3C as a new class of therapeutic molecules that mediate their anticancer effects in estrogenresponsive cell types through the selective control of ER gene expression.
MATERIALS AND METHODS
Materials
DMEM, Iscove's modified Dulbecco's medium, fetal bovine serum, calcium-and magnesium-free PBS, L-glutamine, and trypsin-versene mixtures were purchased from BioWhittaker, Inc. (Walkersville, MD). Insulin (bovine), and 17␤-estradiol, dimethyl sulfoxide, and tamoxifen were purchased from Sigma Chemical Co. (St. Louis, MO). PPT was obtained from Tocris (Ellisville, MO). I3C, DIM, and Tryptophol were purchased from Aldrich (Milwaukee, WI). The sources of other reagents are either listed below or were of the highest purity available.
Cell Culture
MCF7 and T47D human breast adenocarcinoma cells were obtained from the American Type Culture Collection (Manassas, VA). MCF7 cells were grown in DMEM supplemented with 10% fetal bovine serum (BioWhittaker), 10 g/ml insulin, 50 U/ml penicillin, 50 U/ml streptomycin, and 2 mM Lglutamine. T47D cells were grown in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 U/ml streptomycin. The cells were grown to subconfluency in a humidified air chamber at 37 C containing 5% CO 2 . Stock solutions of I3C, DIM, Tryptophol (99.9% HPLC grade), 17␤-estradiol, PPT, and tamoxifen were dissolved in DMSO to yield appropriate concentrations. DMSO was used as vehicle control for all experiments.
ER␣ Gene Promoter Transfections and Luciferase Activity Assays
Plasmids containing 5Ј-deletions of ER␣ gene promoter were a kind gift from Dr. Lisa McPherson, Stanford University. MCF7 cells, grown to confluency in six-well plates, were transfected with 1 g of plasmid constructs containing either Ϫ3.2 kb upstream region of the ER␣ gene with both promoter sites B and A or a 700-bp upstream region containing only start site A. Transfection was performed in serum-supplemented media using Fugene 6 (Roche, Indianapolis, IN) as per manufacturer's instructions. Cells were treated 24 h post transfection with DMSO or 200 M I3C for 48 h. Cells were lysed, and relative luciferase activity was evaluated using Promega luciferase assay kit (Promega Corp., Madison, WI) and a luminometer. Relative luciferase activities were normalized to the protein input with SE. Reproducibility of these results was verified with three independent experiments performed with triplicate samples for each treatment.
ERE-Luciferase/AP-1-Luciferase Transfections and Luciferase Assays
Plasmid (1 g) containing the consensus vitellogenin vit-3ϫERE in pgl2 vector or the consensus AP-1 sites was transfected according to manufacturer's instructions using Fugene 6 (Roche). The media were replaced, 24 h later, with media containing 10% dextran charcoal-stripped fetal bovine serum, and then after an additional 24 h, the cells were treated with DMSO or 200 M I3C for 48 h. The cells were then treated with DMSO, 10 nM 17␤-estradiol, or 100 nM PPT for 24 h, lysed, and subjected to luciferase activity assays using the luciferase assay kit (Promega). The amount of protein was determined using the Lowry method, and the RLUs were normalized to protein input. These transfection assays were carried out three independent times employing triplicate samples for each treatment group.
Western Blotting for ER␣ and ER␤ Protein
After the indicated treatments, MCF7 and T47D cells were harvested in the media, pelleted by centrifugation at 8000 rpm for 5 min, resuspended in 1 ml PBS, and pelleted again by centrifugation. These cells were then resuspended in radio immunoprecipitation buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% Nonidet P-40, 0.1% SDS, and 50 mM Tris) containing protease inhibitors (50 g/ml phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 5 g/ml leupeptin, 0.1 g/ml NaF, and 10 g/ml ␤-glycerophosphate). These extracts were then quantified using the Lowry Method (Bio-Rad Laboratories, Hercules, CA). Normalized amounts of protein were mixed with sample buffer [25% glycerol, 0.075% SDS, 1.25 ml ␤-mercaptoethanol, 10% bromophenol blue, 3.13% 0.5 M SDS, and 0.4% SDS (pH 6.8)], and fractionated on 8% polyacrylamide/0.1% SDS resolving gels using electrophoresis. Prestained protein ladder (Amersham Life Sciences, Arlington Heights, IL) was used as reference for size. Proteins were then transferred electrically to nitrocellulose membranes for 1 h at 4 C. Equal loading was confirmed with Ponceau S incubation of membranes. The blots were then blocked for 1 h in 5% nonfat dry milk dissolved in Western wash buffer [10 mM Tris-HCl (pH 8), 150 mM NaCl, and 0.05% Tween 20] at room temperature. The blots were the rinsed in Western wash buffer and incubated overnight at 4 C in antibodies diluted in Western wash buffer. Rabbit anti-ER␣ and -ER␤ antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz CA) were diluted 1:1000 in wash buffer. CDK2 immunoblotting was performed as described previously (34) . Immunoreactive proteins were detected after incubation with horseradish peroxidase-conjugated secondary antibodies diluted to 3 ϫ 10 Ϫ4 in 1% non-fat dry milk in Western wash buffer (goat antirabbit IgG; Bio-Rad Laboratories). Blots were then treated with enhanced chemiluminescence reagents (NEN Life Sciences, Boston, MA), and all proteins were detected by exposure to Hyperfilm (Eastman Kodak, Rochester, NY). Immunoblotting for ER␣ and ER␤ was repeated using total protein extracts from two independent experiments.
RNA Extraction and RT-PCRs
MCF7 cells were grown in appropriate media and, after the indicated treatment durations, were harvested in 1 ml of Trizol reagent (Invitrogen, San Diego, CA), and the recommended protocol was followed to extract total RNA. RNA was quantified using spectroscopy, and the quality of RNA was confirmed using A260/A280, and by electrophoresis on 1% agarose gels. Total RNA (2 g) was subjected to reverse transcription using Mu-MLV Reverse Transcriptase (Invitrogen) with random hexamers, deoxynucleotide triphosphates, and RNAse Inhibitor (Invitrogen). cDNA (4 l) was then subjected to PCR using primers specific to ER␣, ER␤, PR, and GAPDH as described elsewhere (46) The PCR products were electrophoretically fractionated in 1% Agarose gels along with a 1-kb plus DNA ladder and visualized on a UV transilluminator. RT-PCR was thus performed on total RNA from two independent experiments to confirm the observed expression patterns for ER␣ and ER␤.
Affinity Chromatography for ER-ERE Binding
The pBluescript plasmid containing the consensus vitellogenin ERE was subjected to restriction enzyme digest using BglII and HindIII. The products were electrophoresed on a 1% agarose gel containing ethidium bromide. The 550-bp band corresponding to the ERE was excised and extracted using the Qiaex II kit (QIAGEN, Chatsworth, CA). Approximately 16 g of ERE fragment was biotinylated using Klenow enzyme as per manufacturer's protocol and was extracted by ethanol/salt extraction. Overall, 7 g of DNA was then used for the chromatographic assay. MCF7 and MDA-MB-231 cells treated with I3C or DMSO were lysed using a buffer containing 10 mM HEPES, 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, and 2 mM EDTA, and a cocktail of protease inhibitors without dithiothreitol. Protein content of cell lysates was then normalized using the Lowry method (Bio-Rad Laboratories). Streptavidin-conjugated agarose beads (Sigma) were resuspended in 400 l of lysis buffer, and the column was divided into two Eppendorf tubes with 200 l each. Approximately 2 mg of total protein from DMSO-or I3C-treated cells was added to each column and incubated at 4 C for 1 h with constant rocking using a nutator (Clay Adams, Sparks, MD). The column was then centrifuged at 4 C for 5 min at 5000 rpm. The unbound lysate was stored, and the columns were washed three times using lysis buffer. The elution buffer was prepared by adding 400 mM NaCl to the lysis buffer and added to the beads. After incubation at room temperature for 5 min, the beads were centrifuged, and the supernatant was loaded and subjected to SDS-PAGE. The amount of bound ERs was assayed by immunoblotting as described above. Using different batches of cells and drugs, this procedure was repeated five independent times.
Flow Cytometric Analyses of DNA Content
MCF7 cells were plated onto six-well tissue culture dishes (Nunc Fischer, Hampton, NH). The cells were grown in media containing dextran charcoal-stripped 10% fetal bovine serum. Cells were treated with 10 nM E or 100 nM PPT in the presence and absence of 100 M I3C. Cells were incubated for 48 h and hypotonically lysed in 1 ml of DNA staining solution (0.5 mg/ml propidium iodide, 0.1% sodium citrate, and 0.05% Triton X-100). Nuclear emitted fluorescence with wavelength of more than 585 nm was measured with a Coulter Elite instrument with laser output adjusted to deliver 15 mW at 488 nm. Nuclei (10,000) were analyzed from each sample at a rate of 300-500 nuclei. The percentages of cells within the G1, S, and G2-M phases of the cell cycle were determined by analysis with the Multicycle computer program provided by Phoenix Flow Systems in the Cancer Research Laboratory Microchemical Facility of the University of California, Berkeley. This experiment was repeated twice to confirm observed results.
